
Abbott Labs (ABT) Stock Rising on Q2 Earnings Beat
NEW YORK (TheStreet) -- Shares of Abbott Laboratories (ABT) - Get Report are gaining 1.6% to $42.47 in pre-market trade after the company reported better-than-expected earnings and revenue for the 2016 second quarter.
Abbott Labs reported second quarter earnings of 55 cents and revenue of $5.3 billion.
Analysts had estimated earnings of 53 cents and revenue of $5.24 billion.
The company also reported a 3.2% rise in quarterly sales, aided by Abbott's strong branded generics and medical device businesses.
"We're particularly pleased with the steady cadence of new product approvals and recent launches that are contributing to growth, including Freestyle Libre, MitraClip, Absorb and Symfony," said CEO Miles White in a company statement.
Abbott Labs is a healthcare company based in Abbott Park, IL.
Separately, TheStreet Ratings rated this stock as a "hold" with a ratings score of C+.
The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, TheStreet Ratings finds weaknesses including deteriorating net income, weak operating cash flow and a generally disappointing performance in the stock itself.
You can view the full analysis from the report here: ABT
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.










